Trial reportDiabetes care2013
Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD).
Trial report in Diabetes care, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 51 citations in OpenAlex.
- Salsalate treatment improves glycemia without altering adipose tissue in nondiabetic obese hispanics.Obesity (Silver Spring, Md.) · 2015Trial
- Phytotherapeutic insights into hyperuricemia: a mechanistic and clinical perspective.Inflammopharmacology · 2025Review
- Neuroinflammation and metabolic dysregulation as predictors of cognitive impairment, depression, and quality of life in type 2 diabetes mellitus patients on SGLT2 inhibitors and sulfonylureas.Inflammopharmacology · 2025Article
- Targeting inflammation in atherosclerosis: overview, strategy and directions.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2024Review
- Short-term salicylate treatment improves microvascular endothelium-dependent dilation in young adults with major depressive disorder.American journal of physiology. Heart and circulatory physiology · 2022Article
- Article
- Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease.Frontiers in cardiovascular medicine · 2019Review
- Krüppel-Like Factors in Metabolic Homeostasis and Cardiometabolic Disease.Frontiers in cardiovascular medicine · 2018Review
- Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism.British journal of pharmacology · 2017Review
- Inflammation and insulin resistance: New targets encourage new thinking: Galectin-3 and LTBBioEssays : news and reviews in molecular, cellular and developmental biology · 2017Review
- Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit?Endocrine · 2017Review
- Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk.The Journal of clinical investigation · 2017Review
- Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis.Clinical & translational immunology · 2016Review
- The obesity-induced transcriptional regulator TRIP-Br2 mediates visceral fat endoplasmic reticulum stress-induced inflammation.Nature communications · 2016Article
- LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes.Nature medicine · 2015Article
- Prevention of age-related endothelial dysfunction by habitual aerobic exercise in healthy humans: possible role of nuclear factor κB.Clinical science (London, England : 1979) · 2014Article
- Targeting inflammation in diabetes: Newer therapeutic options.World journal of diabetes · 2014Review
- You're only as old as your arteries: translational strategies for preserving vascular endothelial function with aging.Physiology (Bethesda, Md.) · 2014Review
- Article
- Comment on Goldfine et al. Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diabetes care 2013;36:4132-4139.Diabetes care · 2014Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
Abstract
objectiveTo test whether inhibiting inflammation with salsalate improves endothelial function in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND
methodsWe conducted an ancillary study to the National Institutes of Health-sponsored, multicenter, randomized, double-masked, placebo-controlled trial evaluating the safety and efficacy of salsalate in targeting inflammation to improve glycemia in patients with T2D. Flow-mediated, endothelium-dependent dilation (FMD) and endothelium-independent, nitroglycerin-mediated dilation (NMD) of the brachial artery were assessed at baseline and 3 and 6 months following randomization to either salsalate 3.5 g/day or placebo. The primary end point was change in FMD at 6 months.
resultsA total of 88 participants were enrolled in the study, and data after randomization were available for 75. Patients in the treatment and control groups had similar ages (56 years), BMI (33 kg/m(2)), sex (64% male), ethnicity, current treatment, and baseline HbA1c (7.7% [61 mmol/mol]). In patients treated with salsalate versus placebo, HbA1c was reduced by 0.46% (5.0 mmol/mol; P < 0.001), fasting glucose by 16.1 mg/dL (P < 0.001), and white blood cell count by 430 cells/µL (P < 0.02). There was no difference in the mean change in either FMD (0.70% [95% CI -0.86 to 2.25%]; P = 0.38) or NMD (-0.59% [95% CI -2.70 to 1.51%]; P = 0.57) between the groups treated with salsalate and placebo at 6 months. Total and LDL cholesterol were 11 and 16 mg/dL higher, respectively, and urinary albumin was 2.0 µg/mg creatinine higher in the patients treated with salsalate compared with those treated with placebo (all P < 0.009).
conclusionsSalsalate does not change FMD in peripheral conduit arteries in patients with T2D despite lowering HbA1c. This finding suggests that salsalate does not have an effect on vascular inflammation, inflammation does not cause endothelial dysfunction in T2D, or confounding effects of salsalate mitigate favorable effects on endothelial function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.